ArticleScientific reports2025
Exploring the mechanism of proteinuria reduction by hydroxychloroquine in IgA nephropathy using network pharmacology and molecular mocking.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of hydroxychloroquine in primary glomerular disease - a systematic review and meta-analysis of the current evidence.BMC nephrology · 2025Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the 2021 KDIGO guidelines, hydroxychloroquine (HCQ) had been recommended for the treatment of IgA nephropathy (IgAN). However, the precise mechanisms by which HCQ ameliorated proteinuria in IgAN were not fully understood. This study investigated the potential mechanisms of HCQ in reducing proteinuria in IgAN using network pharmacology and molecular docking approaches. Targets associated with IgAN, proteinuria, and HCQ were identified from databases including DisGeNET, GeneCards, OMIM, and PharmMapper. GO and KEGG analyses were conducted using the DAVID platform. Protein-protein interaction (PPI) networks were constructed using the STRING database, and hub genes were identified using Cytoscape software. The selection of hub genes was corroborated with data from the GEO database and validated through molecular docking. Additionally, miRNAs were predicted using NetworkAnalyst. A total of 48 genes were identified as being associated with the reduction of proteinuria in IgAN. The findings suggested that HCQ's mechanism of action in mitigating proteinuria in IgAN primarily involved pathways related to inflammation. Furthermore, this mechanism was linked to the regulatory effects of miR-130b-3p on the expression of genes such as MMP2, IGF1, and PPARG. HCQ targeted miR-130b-3p, thereby influencing the TLR/MyD88/NF-κB signaling pathway and modulating the expression of MMP2, IGF1, and PPARG. This action may have been responsible for the observed reduction in proteinuria associated with IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.